Adverse Event Reporting
| VAERS ID | 2280546 |
|---|---|
| Gender | Female |
| Age | |
| StateCode | |
| Pharmaceutical Company | PFIZER\BIONTECH |
| Lot Number | FH8027 |
| Number of vaccinations | 3 |
| Vaccinated | |
| Onset | 2021-08-13 |
| Condition | Permanent Disability |
Symptoms
- Asthenia
- Rash erythematous
- Vaccination site erythema
- Dermatomyositis
Current Illness
Preexisting Conditions
Medical History/Concurrent Conditions: Hashimoto's disease (Other medical history: hashimotos); Hypothyroidism (Other medical history: hypothyroidism); Pollen allergy (Known allergies: pollen); Vitiligo (Other medical history: vitiligo)
Other Medications
PANTOPRAZOLE; LEVOTHYROXINE; ZYRTEC [CETIRIZINE HYDROCHLORIDE]
Previous Vaccinations
Allergies
Laboratory Data
Write-up
have been diagnosed with Dermatomyositis; had red rashing everywhere; I also had a red ring around the injection site for 4.
5 months; I began to lose strength in my arms and legs; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).
A 66-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), as dose 3 (booster), single (Lot number: FH8027) intramuscular for covid-19 immunisation.
The patient's relevant medical history included: "Other medical history: hypothyroidism" (unspecified if ongoing), notes: Other medical history: hypothyroidism; "Other medical history: hashimotos" (unspecified if ongoing), notes: Other medical history: hashimotos; "Other medical history: vitiligo" (unspecified if ongoing), notes: Other medical history: vitiligo; "Known allergies: pollen" (unspecified if ongoing), notes: Known allergies: pollen.
Concomitant medication(s) included: PANTOPRAZOLE; LEVOTHYROXINE; ZYRTEC [CETIRIZINE HYDROCHLORIDE] taken for hypersensitivity.
Vaccination history included: BNT162b2 (Dose Number: 2, Batch/Lot No: EN6202, Route of Administration: Intramuscular), administration date: 08Mar2021, when the patient was 65-year-old, for COVID-19 immunization; BNT162b2 (Dose Number: 1, Batch/Lot No: EL3247, Route of Administration: Intramuscular), administration date: 12Feb2021, when the patient was 65-year-old, for COVID-19 immunization.
The following information was reported: VACCINATION SITE ERYTHEMA (disability) with onset 13Aug2021, outcome "not recovered", described as "I also had a red ring around the injection site for 4.
5 months"; ASTHENIA (disability) with onset 13Aug2021, outcome "not recovered", described as "I began to lose strength in my arms and legs"; RASH ERYTHEMATOUS (disability) with onset 13Aug2021, outcome "not recovered", described as "had red rashing everywhere"; DERMATOMYOSITIS (disability, medically significant) with onset 13Aug2021, outcome "not recovered", described as "have been diagnosed with Dermatomyositis".
The events "have been diagnosed with dermatomyositis", "had red rashing everywhere", "i also had a red ring around the injection site for 4.
5 months" and "i began to lose strength in my arms and legs" required physician office visit and emergency room visit.
Therapeutic measures were taken as a result of dermatomyositis, rash erythematous, vaccination site erythema, asthenia included lots of medical care.
No follow-up attempts are possible.
No further information is expected.